NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Freeport-McMoRan Inc. (NYSE: FCX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Freeport securities between February 15, 2022 and September 24, 2025, bo ...

NEW YORK, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (NASDAQ: TLX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025 ...

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to a range of $1.840 billion to $1.854 billion from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - Investors have until January 5, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Minnesota [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock [3]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8]. Reasons for Stock Drop - The delays in the rollout were attributed to inadequate preparation for clinicians and payors, resulting in significant adoption delays and weak demand due to customers having excess inventory of older devices [6][7].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, titled Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported a revenue of $425.9 million for its Design IP segment in Q3 2025, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6]. - The company indicated that its Design IP customers were requiring more customization, which was affecting the economics of its business model [5].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [4]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," ignored compliance requirements, and had a poor customer experience leading to higher withdrawal rates and lower conversion rates [4]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60, or over 11%, from $158.36 to $139.76 per share [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share, with an estimated impact of 10,000-15,000 fewer enrollments [6].

Core Viewpoint - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ALT5 Sigma Corporation, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1]. Company Overview - ALT5 Sigma Corporation operates in the blockchain technology sector through its Fintech and Biotechnology segments [2]. - The company announced plans to raise approximately $1.5 billion before fees through a registered direct offering and a private placement offering on August 11, 2025 [2]. Recent Developments - On August 29, 2025, ALT5 Sigma disclosed that its subsidiary, ALT5 Sigma Canada Inc., was found criminally liable for illicit enrichment and money laundering by a Rwandan court [3]. - An independent committee was appointed to investigate potential misstatements or omissions in the financial statements and material information by management [3]. - On October 22, 2025, the CEO, Peter Tassiopoulos, was suspended and removed from his duties [3]. - ALT5 Sigma announced on November 18, 2025, that it would not file its Quarterly Report on Form 10-Q on time [3]. - A leadership overhaul occurred on November 27, 2025, with the simultaneous departures of the CFO, Acting CEO, and COO, along with the appointment of a new Acting CEO and CFO [3]. - On November 28, 2025, the company disclosed the resignation of its independent registered public accounting firm, Hudgens CPA, PLLC [3]. - On December 3, 2025, ALT5 Sigma received a notice from Nasdaq regarding non-compliance with listing requirements due to the resignation of a board member [3].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of BioVie Inc. (NASDAQ: BIVI) towards shareholders [1] Group 1: Shareholder Rights and Legal Options - Long-term shareholders of BioVie may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced shareholder value [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]

RADNOR, Pa., Dec. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of CoreWeave, Inc. (NASDAQ: CRWV) (“CoreWeave”). CoreWeave’s business model involves using high-interest debt to buy thousands of advanced AI chips from Nvidia, installing them in server racks inside data centers that it leases from third-party landlords, then renting access to the chips to AI co ...

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of Microvast Holdings, Inc. which may affect shareholder rights [1] Group 1: Legal Actions and Shareholder Rights - Long-term shareholders of Microvast may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2] - Shareholder involvement is crucial for improving company policies and enhancing shareholder value through better oversight [3] Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4]